Navigation Links
Concord Medical Reports Third Quarter 2011 Financial Results
Date:11/14/2011

was RMB39.5 million ($6.2 million) in the first nine months 2011, up 17.2% from RMB33.7 million in the first nine months 2010, mainly due to the higher pretax income. The effective tax rate for the first nine months 2011 was 28.6% compared with 27.9% in the first nine months 2010.

Net income was RMB98.7 million ($15.5 million) in the first nine months 2011, up 13.1% from RMB87.2 million in the first nine months 2010.

Basic and diluted earnings per ADS for the first nine months 2011 were RMB2.08 ($0.33), up 16.2% from basic and diluted earnings per ADS of RMB1.79 in the first nine months 2010.

Adjusted EBITDA (non-GAAP)(C) was RMB243.9 million ($38.2) million for the first nine months 2011, up 12.8% from RMB216.3 million for the same period 2010.

In the first nine months 2011, capital expenditures were RMB212.6 million ($33.3 million), depreciation expense was RMB69.2 million ($10.7 million), and amortization of acquired intangibles was RMB19.1 million ($3.0 million).

Revenue Outlook Maintained for 2011Based on current market and operating conditions, planned business expansion, and estimated patient volume, Concord Medical is maintaining its prior revenue outlook for the year 2011, as shown below.

The Company expects to generate net revenues in an estimated range of RMB480 million to RMB520 million for the year 2011, which would be an increase of approximately 23% to 33% in net revenues from 2010. This estimated range includes revenues from the Chang'an CMS International Cancer Center ("CCICC") preliminary operations but excludes any potential future revenue from the Chang'an Hospital, as the acquisition of Chang'an Hospital's equity interests is currently pending. The Company notes that any unanticipated delays in completing the acquisition of Chang'an Hospital, any failure to obtain CCICC's clinical license, and other uncertainties may result in CCICC not achieving its expected contribution to the Company, which in turn
'/>"/>

SOURCE Concord Medical Services Holdings Limited
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. New Study Shows Concord Grape Juice has a Heart-Healthy Effect not yet Reported With Red Wine
2. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
3. Concord Grape Juice Has No Significant Impact on Body Weight
4. Concord Medical to Report First Quarter 2010 Financial Results on Thursday, May 27, 2010
5. Concord Medical Announces New Centers Opening at Hospital Partner
6. Concord Medical Announces Share Repurchase Program
7. Concord Medical Files 2009 Annual Report on Form 20-F
8. Concord Medical Enters into Joint Venture Agreement with ChangAn Hospital
9. Concord Medical to Report Second Quarter 2010 Financial Results on Wednesday, August 18, 2010
10. Concord Medical Announces Second Quarter 2010 Financial Results
11. Concord Medical to Hold Annual General Meeting on December 11, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... , August 3, 2015 ... between biotech companies, military surgical research and ... therapies with regards to severe wound treatments ... enhancements for regenerative medicine and tissue-engineered skin ... partnerships and advancements in focus are Amarantus ...
(Date:8/3/2015)... SINGAPORE , Aug. 3, 2015 ... Bloomberg: BIG SP; Reuters: BIOS.SI; SGX: B20), a ... today announced financial results for its first fiscal ... Quarter Highlights and Recent Developments: ... progress in improving its cost structure, driven by ...
(Date:8/3/2015)... -- Array BioPharma Inc. (NASDAQ: ARRY ) today ... year of its fiscal year ended June 30, ... Array, noted, "Binimetinib and encorafenib, two innovative oncology ... regulatory submissions in 2016. Additional data shared over ... cancer further validate the value of these programs ...
Breaking Medicine Technology:Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 2Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 3Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 4Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 5Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 6Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 2Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 3Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 4Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 5Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 6Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 2Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 3Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 4Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 5Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 6Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 7Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 8Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 9Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 10Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 11Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 12
... 27, 2011 Reportlinker.com announces that ... available in its catalogue: ... Market Outlook to 2017- Glucose Monitoring ... http://www.reportlinker.com/p0739472/United-States-Diabetes-Care-Devices-Market-Outlook-to-2017--Glucose-Monitoring-and-Insulin-Delivery.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology United ...
... December 27, 2011 ReportsnReports adds ... in Latin America , to its store. This ... in terms of their attractiveness as pharmaceutical markets ... property, and pricing are examined. The report presents ...
Cached Medicine Technology:United States Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 2United States Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 3United States Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 4United States Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 5United States Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 6United States Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 7United States Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 8United States Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 9United States Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 10United States Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 11United States Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 12Latin America Emerging Pharmaceutical Markets - Argentina, Chile, Colombia, Peru, and Venezuela 2Latin America Emerging Pharmaceutical Markets - Argentina, Chile, Colombia, Peru, and Venezuela 3
(Date:8/3/2015)... San Francisco, CA (PRWEB) , ... August 03, 2015 , ... ... MSHA, as the chief operating officer (COO) at CPMC. Hamila will start in her ... four hospital campuses. , Kownacki has worked at CPMC and Sutter Health for ...
(Date:8/3/2015)... ... 2015 , ... Code , an industry leader of image-based barcode reading ... Reader accessory that enables a wireless connection between the CR5000 and a ... of barcode reading applications with iPads, Galaxy Tabs, and many other products that lack ...
(Date:8/3/2015)... ... 03, 2015 , ... They know every second counts. And when it comes ... some of the best care in the nation. For the past two months, the ... blood clot removal time in the country. During the months of June and July, ...
(Date:8/3/2015)... ... August 03, 2015 , ... Pitt Researchers to Monitor ... of Pittsburgh School of Medicine are leading a five-year, $5 million initiative to ... , A cooperative agreement awarded by the U.S. Agency for International Development ...
(Date:8/3/2015)... ... 03, 2015 , ... Catalent Pharma Solutions, the leading global ... health products, today welcomed the announcement by OPKO Health that the US Food ... new treatment for chronic kidney disease (CKD) and vitamin D insufficiency, which uses ...
Breaking Medicine News(10 mins):Health News:Hamila Kownacki, RN Appointed as New Chief Operating Officer at CPMC 2Health News:Code Launches the T500, an Innovative Code Reader Accessory 2Health News:Code Launches the T500, an Innovative Code Reader Accessory 3Health News:Providence St. Vincent Stroke Care Recognized Among Best in the Country 2Health News:Providence St. Vincent Stroke Care Recognized Among Best in the Country 3Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 2Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 3Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 4Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 2Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 3
... Human Resources continues to,be a big cost center, ... cost reductions and productivity improvements. So how can ... comprehensive HR metrics study by benchmarking leader Best Practices,LLC ... of performance,metrics for your key HR functions: Staffing, Benefits, ...
... Just six hours of instruction improved relationships with patients, ... -- New evidence suggests that a bit of theatrics ... is based on the experience of a small group ... of theater workshops and lectures led by university theater ...
... Today in Major Indian Newspapers Includes, Chart Comparing Cipla ... ... India, Sept. 6 As part of its,ongoing global campaign to ... Healthcare Foundation (AHF),has published a print advertisement in the form of ...
... forward,to Saturday, September 8,s Michigan Policy Summit as a ... education, women,s and,civil rights, labor and social justice organizations ... a common action agenda around the,issues of education, energy ... hangs in the balance," stated AFT Michigan,President David Hecker. ...
... Prime Therapeutics (Prime), a,thought leader in ... in Pharmaceutical Purchasing Standards SM (TIPPS SM),certification. ... the HR Policy Association,Pharmaceutical Coalition, an alliance ... initiative calls for adherence to nine drug ...
... Sept. 6 Par,Pharmaceutical Companies, Inc. (NYSE: PRX ... its 2006 Annual Report on Form 10-K. The,filing of ... to the work,involved in restating its consolidated financial statements ... Par intends to file its,Form 10-Q for the first ...
Cached Medicine News:Health News:End-to-End HR Performance Benchmarks: Metrics That Will Help Turn the HR Cost Center into a Productivity Driver 2Health News:Theater Classes Help Docs' Bedside Manners 2Health News:Theater Classes Help Docs' Bedside Manners 3Health News:'Cipla, Tell the Truth'; AIDS Healthcare Foundation Launches New Ad Campaign 2Health News:'Cipla, Tell the Truth'; AIDS Healthcare Foundation Launches New Ad Campaign 3Health News:'Cipla, Tell the Truth'; AIDS Healthcare Foundation Launches New Ad Campaign 4Health News:'Cipla, Tell the Truth'; AIDS Healthcare Foundation Launches New Ad Campaign 5Health News:'Cipla, Tell the Truth'; AIDS Healthcare Foundation Launches New Ad Campaign 6Health News:'Cipla, Tell the Truth'; AIDS Healthcare Foundation Launches New Ad Campaign 7Health News:Prime Therapeutics Receives TIPPS Certification 2Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 2Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 3Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 4Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 5Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 6Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 7Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 8Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 9Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 10Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 11Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 12